Acadian Asset Management
INDV icon

Acadian Asset Management’s Indivior Pharmaceuticals INDV Stock Holding History

Acadian Asset Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.1M Sell
733,974
-657,638
-47% -$23.9M 0.04% 347
2026
Q1 		$42.4M Sell
1,391,612
-1,693,501
-55% -$55.9M 0.06% 256
2025
Q4 		$110M Buy
3,085,113
+201,653
+7% +$6.16M 0.18% 113
2025
Q3 		$69M Buy
2,883,460
+1,391,188
+93% +$29.1M 0.12% 160
2025
Q2 		$22M Buy
1,492,272
+827,230
+124% +$9.63M 0.05% 296
2025
Q1 		$6.33M Buy
+665,042
New +$6.99M 0.02% 431
2024
Q3 		– Sell
-277,197
Closed -$4.34M – 2203
2024
Q2 		$4.34M Sell
277,197
-898,260
-76% -$16.2M 0.01% 539
2024
Q1 		$25.1M Sell
1,175,457
-468,602
-29% -$8.8M 0.09% 183
2023
Q4 		$24.8M Sell
1,644,059
-637,120
-28% -$11.3M 0.1% 183
2023
Q3 		$49.5M Sell
2,281,179
-47,527
-2% -$1.08M 0.21% 126
2023
Q2 		$54M Buy
+2,328,706
New +$53.4M 0.22% 124

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management's INDV Position: Q2 2026 in Review

Acadian Asset Management reduced its Indivior Pharmaceuticals (INDV) stake by 47% in Q2 2026, selling an estimated $23.9M and leaving 733,974 shares worth $30.1M. The position accounts for 0.04% of the portfolio, ranked #347.

Acadian Asset Management first reported a position in INDV in Q2 2023 and has held it in 11 quarters since. The position peaked at $110M in Q4 2025. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Acadian Asset Management held 733,974 shares of Indivior Pharmaceuticals worth $30.1M as of Q2 2026.
  • Acadian Asset Management sold 657,638 Indivior Pharmaceuticals shares in Q2 2026, an estimated $23.9M.
  • Indivior Pharmaceuticals made up 0.04% of Acadian Asset Management's portfolio in Q2 2026, its #347 holding.
  • Acadian Asset Management first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 11 quarters since.
  • Acadian Asset Management's Indivior Pharmaceuticals position peaked at $110M in Q4 2025.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.